365 Days of OncoDaily: Ending 2024 Strong

As 2024 comes to end, we reflect on an extraordinary year for OncoDaily.

Staying truthful to our mission to inspire unity and initiative for a future where cancer care is more accessible, equitable, and compassionate, we grew exponentially creating a larger community around us empowered by new partnerships and collaborations. And what is the most important thing about OncoDaily? We are committed to bringing positive news to people’s lives while staying true to current scientific evidence and realities.

“We established OncoDaily in May 2023, and in just one year, we have made significant progress. Starting from scratch, OncoDaily has quickly become one of the leading oncology media platforms globally.” – said Gevorg Tamamyan, Editor-in-chief of OncoDaily

Let’s take a quick look at this year’s highlights of OncoDaily! 

First things first

The year 2024 began with a historic moment that set the tone for the months to come – the inaugural Global OncoThon, hosted by OncoDaily on February 15th, in honor of International Childhood Cancer Day.

This 24-hour live-streamed event united over 100 speakers from 40 countries, including global leaders, researchers, survivors, and advocates, in a shared mission to transform the landscape of childhood cancer care.

The Global OncoThon was more than just an event – it was a powerful demonstration of what can be achieved when the world comes together for a common cause.

Thanks to the collective efforts of participants, donors, and supporters, the OncoThon raised $1.3 million.

These funds will directly support Oncoheroes Biosciences in launching an international clinical trial to evaluate volasertib, a promising treatment for five pediatric cancer types.

“We extend our heartfelt gratitude to every individual who contributed to the success of this extraordinary event.

A special thanks to the team at OncoDaily for their exceptional efforts in organizing and hosting this event. Your dedication and passion have been instrumental in making the Oncothon 2024 a resounding success.”  – Oncoheroes Biosciences 

This monumental event set the stage for the year to come.

Manifesto in The Lancet

After the first Global Summit on War and Cancer organised by OncoDaily and the Institute of Cancer and Crisis, our manifesto was published in The Lancet. This call to action demands immediate measures to protect cancer care amidst the chaos.

“It took us 8 months to publish this important Manifesto after the first Global Summit on War and Cancer organized by the Institute of Cancer and Crisis (ICC) and OncoDaily.

I am humbled to have an opportunity to work with an incredible team of authors.” – Jemma Arakelyan, medical oncologist and the chief executive officer of The Institute of Cancer and Crisis

Tedros Adhanom Ghebreyesus, Dina Mired, Richard Sullivan, Alexandra Mueller, Andreas Charalambous, Arman Kacharian, Christos Tsagkaris, Enrique Soto-Perez-de-Celis, Henrik Grigoryan, Julie Gralow, Andre Ilbawi, Khaled Ghanem, Layth Mula-Hussain, Bente Mikkelsen, Mulugeta Yimer, Nazik Hammad, Stella Arakelyan, Tezer Kutluk, Zeena Salman, Mark Lawler, Gevorg Tamamyan, Maria V Babak, Jemma Arakelyan. A manifesto on improving cancer care in conflict-impacted populations. Lancet. 2024 Aug 3;404(10451):427. doi: 10.1016/S0140-6736(24)01023-7.

Science, Science, Science!

June marked the launch of the OncoDaily Medical Journal, an open-access journal dedicated to advancing oncology worldwide.

By sharing breakthrough research and fostering global collaboration, OncoDaily Medical Journal ensures vital discoveries are accessible to researchers, clinicians, and patients alike.

With an exceptional Editorial Board chaired by Dr Matti Aapro, and a dedicated editor-in-chief Dr. Shushan Hovsepyan, our scientific journal strengthens OncoDaily’s mission to drive innovation and impact in the fight against cancer, making it a cornerstone resource for the global oncology community.

The Voice of Oncology

As always, we kept on going covering some of the most prestigious global oncology conferences on-site and online, including ASCO 2024, ESMO 2024, SIOP 2024, European Cancer Summit 2024, among others.

From Chicago

One of the year’s standout moments was the OncoDaily Party and Yvonne Awards Ceremony during ASCO 24, with around 1,200 registered attendees, brough together clinicians and researchers, leaders and trainees, patients and advocates, in Chicago for a memorable evening of networking and celebration.

“Attending OncoDaily Yvonne Awards 2024 was certainly one of my ASCO24 highlights.” – Onyinye Balogun, Co-Founder of Mission-Driven Tech and Assistant Professor of Radiation Oncology at Weill Cornell Medicine.

If you have missed it, have an inside peak to our photos from the party and stay tuned for the next year’s event! (part 1 and part 2).

We had the privilege of presenting our Yvonne Awards which celebrate exceptional achievements and innovation in oncology.

Inspired by the resilience and strength of the yew tree, the Yvonne Award features a distinctive Y-shaped sculpture, symbolizing the determination and longevity required to advance cancer care.

Recognizing those shaping the future of oncology through groundbreaking work, our recipients exemplified excellence across 7 key categories:

1. Breakthrough Research
2. Global Oncology
3. Community Oncology
4. Leadership
5. Mentorship
6. Challenging the Status Quo
7. Humanitarian Award

Additionally, the first printed issue of our magazine was distributed in 3,000 copies worldwide, with stories that resonated so deeply that they were spotted in oncology clinics across leading hospitals all over the world.

To Barcelona

On September 13, OncoDaily hosted its second Party, this time on Barcelona beach during the ESMO 2024 Annual Congress.

More than 1,000 attendees registered to take part in the OncoDaily celebration. The success of this exceptional gathering was evident not only in the impressive turnout but also in the warm and positive feedback from the attendees. During the evening, the launch of the Global Cancer Movement was announced, a collaboration platform that brings attention to the challenges that cancer patients and survivors face and mobilizes resources to solve these problems. We unify global efforts to advance cancer research and bring equal care opportunities FOR EVERY PATIENT WITH CANCER.

“OncoDaily is a wonderful platform! OncoDaily, somehow, opened the doors for all the cancer community to have a space,” – Princess Dina Mired of Jordan.

During the event, Aladina Foundation was honored with OncoDaily’s Yvonne award for Humanitarian Work, recognizing its exceptional contributions to cancer care and support globally.

“I had the honor of presenting the Humanitarian award to the Fundación Aladina – to my dear friend and Aladina’s CEO, Ishtar Espejo and its founder, a great humanitarian Paco Arango– for their life-saving work globally.” – said Gevorg Tamamyan

And Brussels

OncoDaily had the privilege of providing live coverage from the European Cancer Summit, where we captured key insights and discussions from this prestigious event.

We had the pleasure to interview some of the attendees, including Matti Aapro, Richard Sullivan, Penilla Gunther, Ajay Aggarwal, Christos Tsagkaris, Irfan Lone, Amil Družić, David Ritchie, Maksym Horiachok, Nikolai Goncharenko, Ramon Reyes, Giacomo Lazzaro, Gunnar Schroefel, Jan Geissler, Alexis Vrachimis, who shared their thoughts on the impact of the event, the most pressing issues in oncology, and their thought around OncoDaily.

“OncoDaily is my baby” was trending online! Take a look at the video below and let us know… Do you feel like it is yours?

OncoDaily had the honor of conducting interviews with prominent figures in oncology and medicine at the European Cancer Summit, including President-Elect and Past President of ECO Isabel Rubio and Andreas Charalambous and others.

Read, watch and listen

With every challenge came opportunities to learn, innovate, and grow.

Through it all, OncoDaily remained a trusted resource, amplifying the voices of patients, practitioners, and researchers alike.

Whether it was through the launch of new educational tools, the publication of in-depth articles, or engaging discussions with thought leaders, every effort was aimed at making a tangible difference in the lives of those impacted by cancer. We started a special series with the hit article 10 Most Promising Cancer Drugs Not Yet Approved: Solid Tumors – 2024 edition by OncoDaily, followed by an in-depth discussions with experts in the field on where we are and where we are going in cancer treatment.

In 2024 we published more than 25.000 articles increasing our content count to 100 news a day.

We celebrated prominent voices in oncology, those who strive to make a difference in cancer awareness, education and medical leadership. This year too, we had recognized our Xfluencers including 100 Influential Women in Oncology: Key Opinion Leaders to follow on Social Media in 2024, Key opinion leaders in Colorectal Cancer, Lung Cancer, Sarcoma, Breast Cancer, Prostate Cancer, Pediatric Hematology/Oncology.

“I am truly honored to be recognized as one of the 100 Influential Women in Oncology. The mention is a testament to the collective efforts of so many incredible colleagues, mentors, and advocates who share a passion for advancing cancer care and improving outcomes for patients around the world.” – Karen Knudsen, Executive Strategic Advisor and Immediate Past CEO of the American Cancer Society.

Social Media

On digital platforms, our growth has been exponential. We expanded our reach from LinkedIn, X and YouTube to Facebook, Instagram, Threads, TikTok and, more recently, Bluesky. With tailored content for select audience on each platform, we have attracted over thousand newsletter subscribers who have the opportunity to read the select-daily highlights from OncoDaily. Are you subscribed to our newsletter? Let us know what you think and what do you think is missing.

On LinkedIn, our engagement metrics surpassed those of major global news channels, reflecting the value and impact of our content. Meanwhile, on X, we led the #oncology hashtag for more than six months, according to Symplur metrics, further reinforcing our role as a leader in the conversation around cancer care.

Total Engagement Metrics on LinkedIn: December, 2024

In 2024, OncoDaily launched two new X pages dedicated to Immuno-Oncology and Gastrointestinal Oncology.

“Wow! OncoDaily is so popular that they need to create subcategories of OncoDaily!”- Elad Sharon, Medical Oncologist at Dana-Farber Cancer Institute 

YouTube subscribers grew from 200 to 47,000.

On YouTube, OncoDaily launched several new video series from leadership to scientific and clinical discussions, the most promising drugs in oncology, and, most recently, heartfelt conversations with patients and survivors. 

In July, we launched our first podcast, marking a new milestone in our efforts to share valuable insights and discussions on the latest developments in oncology.

OncoDaily podcasts aims to engage listeners with expert opinions, research updates, and key trends shaping the future of cancer care and treatment.

Thank You to our partners!

In March 2024, OncoDaily became the official partner of the International Society of Paediatric Oncology (SIOP)

The Partnership is a significant step towards supporting the global pediatric oncology community. It reflects our shared commitment to advancing research, education, and awareness in the fight against childhood cancers.

By working together, OncoDaily and SIOP aim to provide valuable resources and insights to healthcare professionals, researchers, and advocates dedicated to improving outcomes for children and families affected by cancer worldwide.

OncoDaily became the Official Media Partner for the China Anti-Cancer Association (CACA) in November.

The partnership will focus on promoting oncology developments, fostering cooperation between China and the global community, and expanding OncoDaily’s media reach.

A Chinese-language version of OncoDaily will be launched to serve Chinese doctors, researchers, healthcare professionals, and patients.

The collaboration will also involve co-organizing oncology educational and scientific events and exploring the creation of joint scientific journals to share cutting-edge research.

“CACA has always been at the forefront of promoting cancer research and education in China and beyond. Partnering with OncoDaily enables us to amplify the achievements of Chinese oncology professionals and strengthen international collaboration.” – Prof. Daiming Fan, President of CACA.

“OncoDaily’s mission is to be the voice of oncology globally. By partnering with CACA, we can ensure that Chinese advancements in oncology reach the world, while bringing international developments closer to the Chinese cancer community. Together, we can make a real impact in the fight against cancer.” – Prof. Gevorg Tamamyan

Strategic partnerships with the National Foundation for Cancer Research (NFCR), Asian Fund for Cancer Research Limited (AFCR) and AIM-HI Accelerator Fund (AIM-HI)

With NFCR we aim to help improve global access to cancer research, treatment and educational resources with our shared mission to make a tangible impact on the lives of those affected by cancer worldwide.

Our collaboration with AFCR is designed to enhance the dissemination of cancer research-related information across Asia, create impactful educational content, organize joint events, while promoting awareness and providing access to high-quality cancer research throughout the region.

“We are extremely excited to be partnering with OncoDaily!

This partnership will allow us to better advance cancer breakthroughs from Asia to the world.

We look forward to continued collaboration that will eventually lead to curing all cancers.” – Asian Fund for Cancer Research

With AIM-HI Accelerator Fund we combine the strengths of both organizations to highlight the achievements of entrepreneurs and early-stage oncology companies and drive biotech innovations, which hopefully will help accelerate the development of next-generation cancer therapies and technologies.

Ending strong

In December, OncoDaily proudly hosted the inaugural event of the Global Cancer Movement, focused on addressing the critical challenges in cancer care.

The theme of the event, “Challenging the Status Quo in Colorectal Cancer”, took place from December 6 to 8, 2024. 80 speakers and 450 participants from 30 countries.

Over three impactful days, global leaders in oncology – physicians, researchers, patients, advocates, and representatives from international organizations – came together to explore the current state of colorectal cancer worldwide and discuss how to fuel innovation and development in the field.

We were honored to have Agenus Inc., a Massachusetts-based biopharmaceutical company and leader in immuno-oncology, serve as the Platinum Sponsor for the event.

Dhan Chand, Vice President of Research at Agenus

Global Cancer Movement marked a significant milestone for OncoDaily, embodying our ongoing commitment to driving progress and fostering collaboration in the fight against cancer.

As we reflect on all that we’ve achieved together, we are filled with gratitude for our incredible community. It is your trust, engagement, and passion that fuel our work and inspire us to keep pushing boundaries. Thank you for being a part of this journey.

A special thank you too our devoted and one-of-a-kind staff who make the core of our OncoDaily family.

We are proud to have built a truly extraordinary group of enthusiasts from across the globe whose imagination and drive for excellence have no boundaries.

More than 50 people are working together with one clear purpose: to fight cancer and raise awareness about oncology. Each team member brings their unique skills and experiences, from researchers and medical professionals to advocates and survivors. We are honored to have a wonderful Editorial Board and invaluable friends, who support us in every our step.

What binds us is our shared commitment to making a difference in the cancer community, whether through advancing research, educating the public, or supporting those affected by cancer.

Together, we strive to create a meaningful impact and inspire hope in the fight against cancer.

With 2025 on the horizon, we are more committed than ever to delivering impactful content, forging meaningful connections, and advancing the fight against cancer. Here’s to another year of growth, discovery, and hope!

Cancer doesn’t take a day off, neither do we.